immunotox report

C'est parti pour la 5ème édition du symposium ITOX sur les #toxicités des #immunothérapies dans le #cancer #ITOX22 ▶️enseignement.gustaveroussy.fr/s/formation-ac…

Symposium iTOX 2022 à la @ciup_fr ! Identifier et comprendre les toxicités des immunothérapies anti tumorales @GustaveRoussy #immunotherapy #toxicities #irAE #CancerImmunotherapy

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers ⁦@CD_AACR⁩ ⁦@Jia_Luo⁩ cancerdiscovery.aacrjournals.org/content/early/…

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer ⁦@JAMAOnc⁩ jamanetwork.com/journals/jamao…

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1 ⁦@Annals_Oncology⁩ annalsofoncology.org/article/S0923-…

An important conversation to take part in, the goal is to: 1. Identify the clinical issues for management of patients receiving IO in the context of covid19 2. Identify the important clinical and translational research questions, and how to tackle them

COVID-19 Implications for I-O Patient Management ⁦@sitcancer⁩ sitcancer.org/communities/co…

@lindacoate Any preliminary signal to report @PAscierto ?

@lindacoate There’s currently no reported data on the impact of #COVID19 in cancer patients treated by anticheckpoint therapy. This is definitely something to watch carefully.

@iTOXreport Are you receiving/collating any data in context of #COVID19 please?

Four years’ experience of @GustaveRoussy in handling immune-related adverse events of ICB. Interestingly, initiation of #immunotherapy in patients with autoimmune comorbidity was assessed as feasible in 93% of cases sciencedirect.com/science/articl…

🎥 Pourquoi l'#immunothérapie peut-elle provoquer des effets secondaires ? Quels sont les plus fréquents ? Comment les gérer ? Les explications en vidéo du Dr Aurélien Marabelle @GustaveRoussy et du Pr Olivier Lambotte, spécialistes en immunothérapie : ▶️youtu.be/Zn82V9X54bI

[Symposium] 4th edition of ITOX on Cancer Immunotherapy Adverse Events gathering Clinicians, Scientists and Pharmacists to share experiences about toxicities May 14, 2020 from 2 PM to May 15,2020 5 PM - Paris Online registration until May 04, 2020 ⏩ formation.gustaveroussy.fr/shop/symposium…

[symposium] 4ème édition iTOX 2020 sur toxicités des immunothérapies anticancéreuses - 14 et 15 mai - Paris 15e à destination des médecins, pharmaciens et chercheurs inscriptions : formation.gustaveroussy.fr/shop/symposium…

Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities ⁦@PNASNews⁩ pnas.org/content/116/44…

Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease ⁦@ASCO_pubs⁩ ascopubs.org/doi/full/10.12…

It is AMAZING how much information we can learn in each iTOX Committee!! Every time I feel l am still on my first-year of residency 🤓📝 learning 📈exponentially on #immunoOncology and toxicity @iTOXreport @GustaveRoussy

Nice talk by Julie Belliere @CHUdeToulouse at @IUCTOncopoleICR on immunosuppressive drugs for irAE. Other IS than TNFa inhibitors should be considered in cortico-resistant irAE especially IL6 inh. @iTOXreport

Comprendre le fonctionnement du système immunitaire et des immunothérapies: c’est l’objectif de notre livre #Immunothérapies avec Nicolas Noël Disponible dans toutes les bonnes librairies ;) editions-tredaniel.com/immunotherapie…

Can pts who develop immune-related adverse events (AEs) on PD-1 or PD-L1 inhibitor immunotherapy be re-challenged later? Cohort of 93 pts from @GustaveRoussy tested, w 55% developing AEs w 2nd administration, typically less severe than 1st exposure ja.ma/2IooajP

Aujourd'hui @GustaveRoussy, se tient la 3ème édition du symposium iTOx pour tout savoir sur les toxicités des #immunothérapies anticancéreuses | #cancer #oncologie